ROP-ET: a prospective phase III trial investigating the ...
The ROP-ET trial evaluates ropeginterferon alfa-2b's efficacy and safety in ET patients intolerant or resistant to other treatments. It aims for durable blood count remission, symptom improvement, and assesses disease modification over 36 months. Patients receive subcutaneous injections, with dose adjustments based on response and tolerability.
Reference News
ROP-ET: a prospective phase III trial investigating the ...
The ROP-ET trial evaluates ropeginterferon alfa-2b's efficacy and safety in ET patients intolerant or resistant to other treatments. It aims for durable blood count remission, symptom improvement, and assesses disease modification over 36 months. Patients receive subcutaneous injections, with dose adjustments based on response and tolerability.